Insider Purchases: Inside the Buy
Tag: Biotech Stocks
🧬 Kura Oncology (KURA) Stock Analysis: From Clinical Promise to Commercial Reality
Kura Oncology is evolving from a clinical-stage biotech into a commercial oncology company. With KOMZIFTI gaining traction, over $500 million in cash, strong institutional ownership and multiple Phase 3 catalysts ahead, is KURA becoming one of biotech's most compelling long-term opportunities?
CORT Stock 2026: FDA Rejection, Insider Buying… and a Brewing Short Squeeze?
Corcept Therapeutics just got hit with an FDA rejection—but insiders are buying millions and short interest is surging. With a profitable base business and major 2026 catalysts ahead, CORT may be one of the most explosive “binary bets” in biotech today.
AbCellera (ABCL) Stock Analysis: 7 Triggers for a Biotech Short Squeeze or Long-Term Multibagger?
Down 95%, heavily shorted, yet sitting on $700M in liquidity and insider conviction — AbCellera (ABCL) may be biotech’s ultimate asymmetric bet.
Insider Buys Shares of Mainz Biomed: Promising Science, Precarious Finances
Mainz Biomed’s cancer-screening science is compelling — and an insider just bought big. But with heavy losses, dilution risk, and a going-concern warning, MYNZ is a biotech moonshot best approached with extreme caution.
Can XOMA Become Royalty? The CEO, BVF Partners, and Morgan Stanley Think So!
XOMA Royalty doesn’t run clinical trials—it collects royalties. With a $2.5M CEO insider buy, heavyweight institutional backing, and improving cash flow, this biotech quiet achiever may be turning into something… royal.
Biohaven Just Went Through Hell — But Its CEO and Directors Still See an Angel
Biohaven’s stock plunged after a brutal FDA rejection — but insiders didn’t blink. They bought millions of dollars’ worth of shares, doubled down on their pipeline, and kickstarted a leaner, more focused strategy. Bold turnaround play or biotech heartburn waiting to happen? Here's the FUNanc1al deep dive.
Absci: When AI Meets Antibodies — and Insiders Can’t Resist Buying More!
AI is designing drugs, and Absci is leading the charge — with insider confidence, top-tier partners, and a cash runway through 2028. Still pre-revenue but packed with promise, this biotech might just be the next NVIDIA of antibodies.
Cogent Biosciences (COGT): The Biotech with a Plan, a Billion Cells, and a Bezuclastinib
Insiders are buying, trials are working, and Cogent just raised $230M. Meet bezuclastinib—the biotech drug with a Marvel name and real potential. 🧬💥
Moderna: Messenger RNA Medicines Powerhouse Sends A New Message — “Discount!”
Insiders dropped $6M on Moderna stock. With a massive mRNA pipeline and deep-pocketed backers, is this biotech beast ready to roar again?
🧬 GeneDx (WGS): Profit, Progress, and a 43% Plunge? Sounds Genetic.
GeneDx is profitable. Revenues are growing. Innovation is real. So why did the stock tank 43%? Here’s your deep-dive into the DNA of a biotech rollercoaster—with humor, icons, and a whole lot of exome.